Fortrea (NASDAQ:FTRE) Posts Quarterly Earnings Results

Fortrea (NASDAQ:FTRE) issued its earnings results on Thursday. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.22 by $0.06, FiscalAI reports. Fortrea had a positive return on equity of 10.72% and a negative net margin of 3.18%. The business had revenue of $691.50 million during the quarter, compared to analysts’ expectations of $671.57 million.

Here are the key takeaways from Fortrea’s conference call:

• Fortrea raised and narrowed its 2026 outlook, now expecting revenue of $2.665 billion to $2.690 billion and adjusted EBITDA of $210 million to $218 million, reflecting improved execution and confidence in its return-to-growth strategy.
• Third-quarter adjusted EBITDA rose 14.4% year over year to $58 million, with margin expanding 120 basis points to 8.4% as portfolio mix, cost controls, and efficiency initiatives more than offset higher compensation investments.
• Demand trends improved, with $773 million in net new business awards, a 1.12 times book-to-bill ratio, stronger biotech bookings, and increasing biopharma RFP activity. Management said the broader pipeline and improving market recovery support future growth, although no 2027 guidance was provided.
• Fortrea completed its acquisition of Worldwide Clinical Trials’ Early Phase Services business, expanding its network to more than 570 beds and adding in-house bioanalytical and safety-lab capabilities that management expects to broaden its addressable market and support future profitability.
• Fortrea recorded a cumulative $558 million backlog adjustment, reducing reported backlog to $7.3 billion. Management said the adjustment reflects inactive studies and work no longer expected to be delivered and does not affect current revenue recognition or near- and medium-term planning, but it highlights uncertainty in the long-term backlog.

Fortrea Stock Down 10.7%

Shares of NASDAQ FTRE traded down $2.78 during mid-day trading on Thursday, reaching $23.10. 3,425,850 shares of the company were exchanged, compared to its average volume of 1,547,397. The company has a quick ratio of 0.96, a current ratio of 0.96 and a debt-to-equity ratio of 1.98. The stock has a market cap of $2.20 billion, a price-to-earnings ratio of -25.24, a P/E/G ratio of 0.57 and a beta of 1.93. Fortrea has a 1 year low of $8.55 and a 1 year high of $26.16. The firm has a 50-day moving average of $20.12 and a 200 day moving average of $15.70.

Insiders Place Their Bets

In other Fortrea news, CEO Anshul Thakral sold 99,869 shares of Fortrea stock in a transaction dated Wednesday, August 5th. The stock was sold at an average price of $19.16, for a total value of $1,913,490.04. Following the transaction, the chief executive officer owned 316,797 shares in the company, valued at $6,069,830.52. The trade was a 23.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.73% of the stock is currently owned by insiders.

Analysts Set New Price Targets

FTRE has been the subject of several recent research reports. TD Cowen lifted their price objective on Fortrea from $19.00 to $23.00 and gave the company a “buy” rating in a report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft upgraded shares of Fortrea from a “hold” rating to a “buy” rating and increased their target price for the stock from $20.00 to $25.00 in a report on Thursday, October 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Fortrea in a research report on Thursday, October 15th. Wall Street Zen upgraded shares of Fortrea from a “hold” rating to a “buy” rating in a report on Saturday, October 10th. Finally, Mizuho upped their price target on shares of Fortrea from $13.00 to $16.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $22.80.

Key Fortrea News

Here are the key news stories impacting Fortrea this week:

• Positive Sentiment: Fortrea reported third-quarter adjusted earnings of $0.28 per share, above consensus estimates ranging from $0.22 to $0.24 and up from $0.12 a year earlier. Revenue totaled $691.5 million, surpassing the $671.6 million analyst forecast. Fortrea Q3 Earnings and Revenues Surpass Estimates
• Positive Sentiment: The quarterly performance indicates stronger-than-expected execution and year-over-year earnings growth, which could support the investment case if Fortrea can sustain momentum in subsequent quarters. Fortrea Reports Third Quarter 2026 Results
• Neutral Sentiment: Despite the earnings beat, Fortrea continued to report a negative net margin of 3.18%, highlighting that profitability remains an issue even as adjusted quarterly earnings improve. Fortrea Quarterly Results
• Negative Sentiment: Fortrea revised its full-year 2026 earnings guidance. The change appears to have disappointed investors, with the market treating the updated outlook as more important than the third-quarter beat. The guidance revision raises concerns about the company’s expected earnings trajectory for the remainder of the year. Fortrea Revises Full-Year 2026 Earnings Guidance
• Negative Sentiment: The immediate decline in FTRE suggests investors were positioned for a stronger outlook and are concerned that the revised guidance may limit near-term upside, despite the company exceeding third-quarter estimates. Fortrea Shares Drop After Q3 Results

About Fortrea

Fortrea Holdings Inc is a global contract research organization (CRO) that provides services to pharmaceutical, biotechnology and medical device companies. The company helps clients plan, manage and execute clinical development programs, supporting the testing of new medicines and therapies from early-stage research through regulatory approval and post-approval activities.

Its services include Phase I through Phase IV clinical trials, clinical operations, patient recruitment and access, data management, biostatistics, medical monitoring, pharmacovigilance and regulatory support.